Emeric Limagne
Emeric Limagne is an expert in Oncology at Centre Georges François Leclerc (France). Emeric Limagne has authored 88 publications, the most recent in 2026. SLR score: 306 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Biochemistry - Immunology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2009 - 2026
Number : 88
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Phosphatidylcholine and CHPT1 as Central Drivers of Chemoresistance in Colorectal Cancer: Lipidomic and Functional Insights. PMID 41827872 — choline, cells, lysophospholipids, pharmaceutical preparations, neoplasms, phosphatidylcholines, colorectal neoplasms, lipidomics | Cells | 2026 | 0 |
| Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes. PMID 41545305 — genes, t-lymphocytes, regulatory, coenzyme a, lymphocytes, stearoyl-coa desaturase, neoplasms, immunotherapy, lymph, oleic acid, t-lymphocytes | J Immunother Cancer | 2026 | 0 |
| Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer. PMID 41271647 — cells, lung, biological science disciplines, neoplasms, carcinoma, non-small-cell lung, immunotherapy, dna, mitochondrial, lung neoplasms, small cell lung carcinoma | Nat Commun | 2025 | 0 |
| Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T Cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite Stable Colorectal Cancer. PMID 41196020 — cytokines, cells, microsatellite repeats, macrophages, neoplasms, therapeutics, colorectal neoplasms, t-lymphocytes, tumor-associated macrophages, dinoprostone | Cancer Res | 2025 | 3 |
| Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet. PMID 40590231 — cells, triple negative breast neoplasms, breast neoplasms, neoplasms, drug therapy, immunotherapy, breast, chemotherapy | J Clin Invest | 2025 | 0 |
LeadR Networks
Main global connection map